Lead Plaintiff Deadline: May 17, 2021
Please Upload related files below
Fill in below.
Looking for more?
while BLU-5937’s “high selectivity” contributed to the drug causing little to no taste alteration in chronic cough patients, that high selectivity also contributed to the drug potentially being less efficacious and thus likely not be able to meet the primary endpoint of the Company’s Phase 2 trial.
In order to be included in the lawsuit, you must have incurred a loss on shares of BELLUS Health, either: A) purchased or acquired during the class period listed above, if applicable; or B) pursuant to the Initial Public Offering (IPO) of BELLUS Health, if applicable.
If you suffered a loss in BELLUS Health during the relevant time frame, or pursuant to BELLUS Health’s IPO if listed above, you have until May 17, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.